USP was founded nearly 200 years ago by eleven doctors who wanted to ensure that the nation had access to quality medicines. They put together the first pharmacopeia, a book of recipes for making tinctures, extracts, and other medicines.
Imagine using software on your phone or tablet to treat health conditions that, until now, could only be treated with medications. Now stop imagining, because for some conditions, such as attention deficit disorder and substance dependency, it is already a reality.
Building the marketplace for generic medicines is a key strategy to containing drug costs in the US, one that USP actively supports through our standards-setting work.
Regardless of whether it’s prescription or over-the-counter, the ingredients on a drug product label typically include one, maybe two, active pharmaceutical ingredients (APIs). The rest of the list is comprised of “inactive” ingredients (excipients) which in reality are far from inactive. Variability may be acceptable for products such as printer ink and paintballs, but not pharmaceuticals, making quality standards for excipients critical to ensuring consistent drug quality.
Nanomedicine—the use of nanoscale materials and technologies to treat diseases at the molecular level—has shown promising results in patient care, particularly in oncology. While this potential has led to increased research, there are challenges surrounding nomenclature, characterization and environmental impact. Learn how you can collaborate with USP to help determine a path foward.
USP releases draft Medicare Model Guidelines version 7.0. Read and comment between now and November 2, 2016.
In the past three decades, an increasingly globalized medical marketplace has helped improve patient access to new medicines. Sadly, it has also provided an opportunity for more substandard, adulterated, and counterfeit medical products. This article explains the evolving role of the ICH in helping to tackle this problem through harmonization, and how USP is linked to the effort.